|
|
Original Articles |
Neuropathology in multiple sclerosis: new concepts |
93 |
Hans Lassmann
|
Abstract
Full Article (PDF)
|
|
Cerebrospinal fluid - physiology, analysis and interpretation of protein patterns for diagnosis of neurological diseases |
99 |
Hansotto Reiber
|
Abstract
Full Article (PDF)
|
|
Composite cerebrospinal fluid score in relapsing-remitting and secondary progressive multiple sclerosis |
108 |
PJH Jongen,
S Floris,
WH Doesburg,
WAJG Lemmens,
OR Hommes & KJB Lamers
|
Abstract
Full Article (PDF)
|
|
The intrathecal, polyspecific and oligoclonal immune response in multiple sclerosis |
111 |
H Reiber,
S Ungefehr & Chr Jacobi
|
Abstract
Full Article (PDF)
|
|
CSF-enriched antibodies do not share specificities among MS patients |
118 |
I Cortese,
S Capone,
S Luchetti,
LME Grimaldi,
A Nicosia & R Cortese
|
Abstract
Full Article (PDF)
|
|
Myelin basic protein in CSF as indicator of disease activity in multiple sclerosis |
124 |
KJB Lamers,
HPM de Reus & PJH Jongen
|
Abstract
Full Article (PDF)
|
|
MBP, anti-MBP and anti-PLP antibodies, and intrathecal complement activation in multiple sclerosis |
127 |
Finn Sellebjerg,
Michael Christiansen & Peter Garred
|
Abstract
Full Article (PDF)
|
|
Can CSF predict the course of optic neuritis? |
132 |
JL Frederiksen
|
Abstract
Full Article (PDF)
|
|
Immune pathogenesis of multiple sclerosis. Brain autoimmune reactivity and its control by neuronal function |
136 |
Hartmut Wekerle
|
Abstract
Full Article (PDF)
|
|
Are there any body fluid markers of brain atrophy in multiple sclerosis? |
138 |
G Giovannoni,
AJE Green & EJ Thompson
|
Abstract
Full Article (PDF)
|
|
Data on cytokine mRNA expression in CSF and peripheral blood mononuclear cells from MS patients as detected by PCR |
143 |
Philippe Monteyne & Christian JM Sindic
|
Abstract
Full Article (PDF)
|
|
Therapy with antibodies against CD40L (CD154) and CD44-variant isoforms reduces experimental autoimmune encephalomyelitis induced by a proteolipid protein peptide |
147 |
JD Laman,
CBM Maassen,
MM Schellekens,
L Visser,
M Kap,
E de Jong,
M van Puijenbroek,
MJB van Stipdonk,
M van Meurs,
C Schwärzler & U Günthert
|
Abstract
Full Article (PDF)
|
|
T cell receptor V 5 and V 17 clonal diversity in cerebrospinal fluid and peripheral blood lymphocytes of multiple sclerosis patients |
154 |
P Lozeron,
D Chabas,
B Duprey,
O Lyon-Caen & R Liblau
|
Abstract
Full Article (PDF)
|
|
Monocyte activation in multiple sclerosis |
162 |
Anthony T Reder,
Kur ad Genç,
Paul V Byskosh & Anna Maria Porrini
|
Abstract
Full Article (PDF)
|
|
Cytokines in multiple sclerosis: pro-inflammation or pro-remyelination? |
169 |
MK Sharief
|
Abstract
Full Article (PDF)
|
|
Time-course analysis of CD25 and HLA-DR expression on lymphocytes in interferon- 1b-treated multiple sclerosis patients |
174 |
AM Ferrarini,
S Sivieri,
M Buttarello,
A Facchinetti,
P Perini & P Gallo
|
Abstract
Full Article (PDF)
|
|
Correlation of soluble adhesion molecules in blood and cerebrospinal fluid with magnetic resonance imaging activity in patients with multiple sclerosis |
178 |
Peter Rieckmann,
Bernd Altenhofen,
Antje Riegel,
Boris Kallmann & K Felgenhauer
|
Abstract
Full Article (PDF)
|
|
Serum soluble intercellular adhesion molecule-1 in MS: relation to clinical and Gd-MRI activity and to rIFN -1b treatment |
183 |
M Trojano,
C Avolio,
M Ruggieri,
G Defazio,
F Giuliani,
D Paolicelli & P Livrea
|
Abstract
Full Article (PDF)
|
|
Monitoring Multiple Sclerosis course and activity with TNF-alpha |
188 |
Michel Chofflon & Benoît Fellay
|
Abstract
Full Article (PDF)
|
|
Relapse markers in multiple sclerosis: are in vitro cytokine production changes reflected by circulatory T-cell phenotype alterations? |
193 |
Jan Debruyne,
Jan Philippé,
Jacques Dereuck,
Annick Willems & Geert Leroux-Roels
|
Abstract
Full Article (PDF)
|
|
In vitro cytokine profiles as indicators of relapse activity and clinical course in multiple sclerosis |
198 |
Myriam Schluep,
Guy van Melle,
Hugues Henry,
Claudio Städler,
Béatrice Roth-Wicky & Pierre J Magistretti
|
Abstract
Full Article (PDF)
|
|
Myelin reactive T cells in the autoimmune pathogenesis of multiple sclerosis |
203 |
Piet Stinissen,
Robert Medaer & Jef Raus
|
Abstract
Full Article (PDF)
|
|
The potential role of nitric oxide in multiple sclerosis |
212 |
G Giovannoni,
SJR Heales,
JM Land & EJ Thompson
|
Abstract
Full Article (PDF)
|
|
A unique population of circulating autoantibodies promotes central nervous system remyelination |
217 |
K Asakura & M Rodriguez
|
Abstract
Full Article (PDF)
|
|
A gene therapy approach to treat demyelinating diseases using non-replicative herpetic vectors engineered to produce cytokines |
222 |
G Martino,
R Furlan,
F Galbiati,
PL Poliani,
A Bergami,
LME Grimaldi,
L Adorini & G Comi
|
Abstract
Full Article (PDF)
|
|
Are there indicators of remyelination in blood or CSF of multiple sclerosis patients? |
228 |
AR Massaro
|
Abstract
Full Article (PDF)
|
|
Disease activity and the immune set in multiple sclerosis: blood markers for immunotherapy |
232 |
AJ Coles,
MG Wing & DAS Compston
|
Abstract
Full Article (PDF)
|
|
The expression of integrins on activated T-cells in multiple sclerosis. Effect of intravenous methylprednisolone treatment |
239 |
S Luján,
J Masjuan,
E Roldán,
LM Villar,
P González-Porqué & JC Álvarez-Cermeño
|
Abstract
Full Article (PDF)
|
|
Myelin basic protein-like material in the urine of multiple sclerosis patients: relationships to clinical and neuroimaging changes |
243 |
John N Whitaker
|
Abstract
Full Article (PDF)
|
|
Urinary markers of disease activity in multiple sclerosis |
247 |
G Giovannoni & EJ Thompson
|
Abstract
Full Article (PDF)
|
|
Free light chains in multiple sclerosis urine |
254 |
PD Mehta,
SD Cook,
PK Coyle,
RA Troiano,
CS Constantinescu & AM Rostami
|
Abstract
Full Article (PDF)
|
|
Identification of brain atrophy with MRI in MS |
257 |
Alan J Thompson
|
Abstract
Full Article (PDF)
|
|
Neurophysiological and cognitive markers of disease evolution in multiple sclerosis |
260 |
G Comi,
V Martinelli,
T Locatelli,
L Leocani & S Medaglini
|
Abstract
Full Article (PDF)
|
|
Body fluid markers to monitor multiple sclerosis: the assays and the challenges |
266 |
JD Laman,
EJ Thompson & L Kappos
|
Abstract
Full Article (PDF)
|
|